Subscribe To
Church & dwight co., inc. (chd) q3 2023 earnings call transcript
Church & Dwight Co., Inc. (NYSE:CHD ) Q3 2023 Earnings Conference Call November 3, 2023 10:00 AM ET Company Participants Matt Farrell - President, CEO...
November 3, 2023, 2:18 pm
Apple analysts mixed as weaker guidance weighs on strong margins
Apple Inc (NASDAQ:AAPL)'s fourth-quarter revenue guidance, although below their estimates, is expected to be offset by the company's strong gross marg...
November 3, 2023, 1:13 pm
Aud/usd looks comfy above 64c, as does wti above $80: asian open
Oil prices snapped a 3-day losing streak on Thursday, and whilst WTI crude didn’t quite meet the minimum obj...
November 2, 2023, 11:59 pm
Sec unveils new rules to boost security-based swap market transparency
The Securities and Exchange Commission (SEC) has introduced new regulations governing the registration of security-based swap execution facilities (SB...
November 2, 2023, 7:54 pm
Chw: imperfect, but not a horrible global fund
Calamos Global Dynamic Income Fund offers a high current yield of 11.49%, making it attractive for income-seeking investors. The CHW closed-end fund's...
November 1, 2023, 5:57 pm
Gsk receives a mixed city reaction despite raised outlook
GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively stro...
November 1, 2023, 12:03 pm
Gab: multi-year lows in the premium for this equity cef
Gabelli Equity Trust is an equity closed-end fund focused on long-term capital growth with income as a secondary ...
November 1, 2023, 8:50 am
Cardiol therapeutics reaches new milestone in phase ii study for recurrent pericarditis
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-...
November 1, 2023, 8:41 am
The city of bridgeport selects cadenza innovation for battery energy storage system pilot project
Purpose-built, Safe, Modular Lithium-ion BESS to be Installed Inside the City’s Fire Department Headquarters and Serve as a Model for Delivering Low...
October 31, 2023, 3:15 pm
Intel analysts trim target price on margin, competition concerns
Intel Corporation (NASDAQ:INTC)'s earnings per share (EPS) in 2024 will likely be hurt by gross margin headwinds, according to BofA Securities analyst...
October 27, 2023, 1:36 pm
Hasbro downgraded on concerns toy business turnaround will not occur until 2025
Analysts at the Bank of America (BoA) have downgraded Hasbro (NASDAQ:HAS) and slashed their price target on the toymaker's stock after it reported dis...
October 27, 2023, 12:18 pm
Par pacific holdings: a 'buy' for growth-focused investors
Par Pacific Holdings is well-positioned for growth with successful acquisitions, diversification into renewables, and a strong financial standing. The...
October 25, 2023, 1:38 am
Rba bullock signals readiness to hike again if inflation outlook revised up
RBA Governor Michelle Bullock emphasized the central bank’s ongoing commitment to stabilizing inflation and promoting job growth in her speech today...
October 24, 2023, 10:53 am
Viatris stock has no real catalysts; greater downside risk: analysts
Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities an...
October 23, 2023, 3:19 pm
Usd/jpy looks to approach 150.00 on the stronger us dollar
BoJ Governor Kazuo Ueda reiterated that the central bank remains steadfast in its commitment to achieve a 2% inflation target in a stable and sustaina...
October 23, 2023, 3:29 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am